- Conditions
- Kidney Transplant Recipients
- Interventions
- Tacrolimus (CNI) Withdrawal, Standard Immunosuppressive Therapy
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 9
- States / cities
- Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 20,584
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8
- Interventions
- Linaclotide, Placebo
- Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Carboplatin
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Lowell, Massachusetts • Dover, New Hampshire + 1 more
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer
- Interventions
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Kidney Transplant Rejection
- Interventions
- MDR-101
- Biological
- Lead sponsor
- Medeor Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 18
- States / cities
- Loma Linda, California • Los Angeles, California • Stanford, California + 15 more
- Conditions
- Glioblastoma, Glioma
- Interventions
- Ascorbic Acid, Bevacizumab, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Dietary Supplement · Biological · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Interventions
- HDMP + rituximab as a means of debulking prior to initiating venetoclax.
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
- Interventions
- Glycerol Tributyrate
- Drug
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Phelan McDermid Syndrome
- Interventions
- Recombinant human Growth hormone
- Drug
- Lead sponsor
- Swathi Sethuram
- Other
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Medication Adherence, Kidney Transplantation
- Interventions
- Adherence Intervention, Healthy living education intervention
- Behavioral · Other
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Other
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Diabetes Type 2
- Interventions
- Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 677 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 80
- States / cities
- Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
- Conditions
- Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Malignant Extragonadal Germ Cell Tumor, Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Ovarian Germ Cell Tumor
- Interventions
- palifosfamide
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Non Small Cell Lung Cancer Metastatic
- Interventions
- Ipilimumab, Nivolumab, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pill Capsule Endoscopy Completion Rates
- Interventions
- Metoclopramide, Placebo
- Drug
- Lead sponsor
- Ascension Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Grand Blanc, Michigan
- Conditions
- Breast Carcinoma
- Interventions
- Computed Tomography, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
- Procedure · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Asthma
- Interventions
- Inhaler sensor, Mobile application for asthma adherence
- Device · Behavioral
- Lead sponsor
- CoheroHealth
- Industry
- Eligibility
- 11 Years to 19 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 192
- States / cities
- Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 163 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Durvalumab, Tremelimumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Primary Systemic Amyloidosis
- Interventions
- 4'-iodo-4'-deoxydoxorubicin, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pancreatic Cancer
- Interventions
- Erlotinib, gemcitabine
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Sacramento, California
- Conditions
- Parkinson's Disease, Gait Impairment
- Interventions
- Methylphenidate (MPD), Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Cardiac Disease
- Interventions
- Amiodarone, Cardioversion
- Drug · Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- GSK2110183, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Duarte, California • Atlanta, Georgia + 5 more
- Conditions
- Psoriatic Arthritis, Axial Spondyloarthritis
- Interventions
- Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 30
- States / cities
- Peoria, Arizona • Apple Valley, California • Covina, California + 26 more